ConductScience.org, home

Comparison · NCT02686138-d7fd5d6e

50mg BID vs Placebo: Percentage of Subjects With Overall Response for 9 Out of 12 Weeks

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. 50mg BID vs Placebo: Percentage of Subjects With Overall Response for 9 Out of 12 Weeks. Trial comparisons, record NCT02686138-d7fd5d6e. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02686138-d7fd5d6e

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1840.1440.233wilson
Risk in group 20.05330.03310.0849wilson
Risk difference, group 1 minus group 20.1310.07990.183newcombe hybrid score
Risk ratio, group 1 over group 23.462.035.9log
Odds ratio, group 1 over group 24.012.247.19log
Number needed to treat, for one more participant with the outcome on 50mg BID than on Placebo7.645.4512.5from the risk difference interval

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 150mg BIDTenapanor, 50mg BID (100mg total)~Tenapanor54293OG000
Group 2PlaceboPlacebo~Placebo16300OG001

Outcome

Type
SECONDARY
Title
Percentage of Subjects With Overall Response for 9 Out of 12 Weeks
Description
An overall responder is defined as a weekly responder for the first 9/12 weeks where both CSBM and abdominal pain response criteria were met for the week. The CSBM response criteria are defined as an increase of one or more change in average weekly CSBMs from baseline and a minimum of at least 3 CSBMs that same week. The definition of a CSBM is as follows: A CSBM is a spontaneous bowel movement (SBM) for which the subject responds yes to the following question; Did you feel like you completely emptied your bowels? The abdominal pain response criterion is defined as a decrease of 30% or more of percent change in average weekly worst abdominal pain from baseline.
Time frame
First 12 weeks
Population

Source ClinicalTrials.gov

Trial

Title
A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
NCT number
NCT02686138
Phases
PHASE3
Conditions
Constipation Predominant Irritable Bowel Syndrome
Interventions
Tenapanor, Placebo
Lead sponsor
Ardelyx
Results first posted
2020-04-13

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02686138-d7fd5d6e